# OnCo record early-stage-classical-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "early-stage-classical-hodgkin-lymphoma" ;
  schema:name "Early-stage classical Hodgkin lymphoma (stage I to II)"@en ;
  schema:alternateName "Limited-stage Hodgkin lymphoma"@en, "Stage I to II classical Hodgkin lymphoma"@en, "Early favourable and early unfavourable Hodgkin lymphoma"@en, "Localised Hodgkin lymphoma"@en ;
  schema:description "Early-stage classical Hodgkin lymphoma is Hodgkin lymphoma confined to one or two lymph node regions on one side of the diaphragm, one of the most curable cancers, with most patients cured by a short course of ABVD chemotherapy with or without radiotherapy to the involved nodes. Because patients are young, trials now use PET scans after two cycles to give as little treatment as safely possible."@en ;
  schema:url <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1000067>, <https://doi.org/10.1056/NEJMoa1408648>, <https://en.wikipedia.org/wiki/Hodgkin_lymphoma>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/types-lymphoma/hodgkin-lymphoma/classical-hodgkin-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment>, <https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/protocols-for-surveillance-of-women-at-higher-risk-of-developing-breast-cancer>, <https://lymphoma-action.org.uk/news/annual-breast-screening-missed-following-radiotherapy-hodgkin-lymphoma>, <https://doi.org/10.1056/NEJMoa1505949> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/> ;
  onco:technologies <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/cardiotoxicity/> ;
  onco:trials <https://onco.cc/trials/ahod2131/>, <https://onco.cc/trials/nct03407144/>, <https://onco.cc/trials/hd10/>, <https://onco.cc/trials/hd16/>, <https://onco.cc/trials/eortc-h10/>, <https://onco.cc/trials/radar-hodgkin/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/>, <https://onco.cc/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/>, <https://onco.cc/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/> ;
  onco:pipeline <https://onco.cc/trials/ahod2131/>, <https://onco.cc/trials/nct03407144/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:standardOfCare <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/>, <https://onco.cc/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/> .